CRVS News
Archived Headlines
- Week ahead: IPO calendar fills up 03/11/16
- Cancer immunotherapy biotech Corvus sets terms for $75 million IPO 03/10/16
- Week ahead: IPO market ready for sub-prime time 01/15/16
- US IPO Weekly Recap: 2016 IPO market kicks off with a flurry of biotech filings 01/08/16
- Immuno-oncology biotech Corvus files for a $115 million IPO 01/04/16
Renaissance Capital's 1Q16 US IPO Market Review
The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing ...read more
US IPO Weekly Recap: Small-cap biotech ends slowest Q1 since 2009
In a week shortened by Good Friday, there was one biotech pricing and one initial filing. The first quarter, marked by the least amount of IPO activity since the 1Q 2009, comes to a conclusion next week. Quarter to date, there have been 8...read more
Corvus prices IPO at $15, the low end of the range
Corvus Pharmaceuticals, which is developing checkpoint inhibitors to treat solid tumors, raised $71 million by offering 4.7 million shares at $15, the low end of the range of $15 to $17. Corvus Pharmaceuticals plans to list on the Nasdaq under the symbol CRVS....read more
Week ahead: One pre-sold biotech IPO during a short holiday week
Corvus Pharmaceuticals is the only IPO on the calendar during the shortened holiday week. Since reaching a year-to-date low on February 11, the S&P 500 has gained 12%, while the market cap-weighted Renaissance IPO Index has surged 19%. The VIX Volatility ...read more